Evaluation of human antibody responses to keyhole limpet hemocyanin on a carbohydrate microarray.

Evaluation of human antibody responses to keyhole limpet hemocyanin on a carbohydrate microarray.
复制标题

碳水化合物微阵列上评估人抗体对匙孔血蓝蛋白的反应。

DOI:
10.1002/prca.200900130
复制
发表时间:
2010
期刊:
Proteomics. Clinical applications
影响因子:
--
通讯作者:
Gildersleeve,JeffreyC
Gildersleeve,JeffreyC
中科院分区:
--
文献类型:
--
作者:
Oyelaran,Oyindasola;Gildersleeve,JeffreyC

文献摘要

相似文献

目的:钥孔血蓝蛋白(KLH)被用作疫苗佐剂,作为小半抗原的载体蛋白,并作为膀胱癌的治疗。用KLH免疫在动物中产生针对肿瘤相关碳水化合物抗原(TACA)的抗体,并且这些抗体已被假定为膀胱癌治疗有效性的基础。本研究的目的是评估抗体反应KLH在human.Experimental设计:一个碳水化合物微阵列被用来在14个人与KLH加明矾adjuvant.Results免疫的抗体反应:14个人中的8个产生抗体至少一个TACA。在某些个体中观察到刘易斯X、刘易斯Y、GA1di、GM 3和唾液酸刘易斯A的增加,但一般而言,抗体谱高度可变。免疫前抗体水平的一个子集的阵列抗原有一个统计学上显着的相关性与KLH.Conclusions和临床相关性的抗体反应的幅度:TACA抗体可以在人类中产生,但抗体谱差异很大,从人到人,这可能有助于可变的KLH的临床反应。某些抗原的治疗前抗体水平可能有助于预测哪些患者对KLH有良好反应。
Purpose: Keyhole limpet hemocyanin (KLH) is used as a vaccine adjuvant, as a carrier protein for small haptens, and as a treatment for bladder cancer. Immunization with KLH produces antibodies to tumor‐associated carbohydrate antigens (TACAs) in animals, and these antibodies have been postulated as the basis of efficacy for bladder cancer treatment. The purpose of this study was to evaluate antibody responses to KLH in humans.Experimental design: A carbohydrate microarray was used to profile antibody responses in 14 individuals immunized with KLH plus alum adjuvant.Results: Eight out of fourteen individuals produced antibodies to at least one TACA. Increases to Lewis X, Lewis Y, GA1di, GM3, and sialyl Lewis A were observed in certain individuals, but, in general, antibody profiles were highly variable. Pre‐immunization antibody levels to a subset of array antigens had a statistically significant correlation with the magnitude of the antibody response to KLH.Conclusions and clinical relevance: Antibodies to TACAs can be produced in humans, but antibody profiles differ considerably from person to person, which may contribute to variable clinical responses with KLH. Pre‐treatment antibody levels to certain antigens may be useful for predicting which patients will respond favorably to KLH.